Theravance Biopharma (TBPH) Current Assets (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Current Assets of $417.6 million for Q1 2026, up 177.93% year-over-year from $150.3 million in Q1 2025, and little changed quarter-over-quarter from $418.5 million in Q4 2025.
Theravance Biopharma (TBPH) Current Assets (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Current Assets for 14 consecutive years, with $417.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 177.93% year-over-year to $417.6 million; the TTM figure through Mar 2026 stood at $417.6 million (up 177.93% YoY), while the FY2025 annual figure was $418.5 million, up 159.8% from the prior year.
- Current Assets steadied at $417.6 million in Q1 2026 per TBPH's latest filing, from $418.5 million in the prior quarter.
- Across five years, Current Assets topped out at $511.7 million in Q3 2022 and bottomed at $116.5 million in Q3 2024.
- Historically, Current Assets has averaged $247.2 million across 5 years, with a median of $192.0 million in 2023.
- Annual changes were most pronounced in 2023 — Current Assets slumped 68.4% — and 2025, when it jumped 207.02%.
- Theravance Biopharma's Current Assets stood at $353.5 million in 2022, then plunged by 62.22% to $133.5 million in 2023, then grew by 20.61% to $161.1 million in 2024, then jumped by 159.8% to $418.5 million in 2025, then slipped by 0.2% to $417.6 million in 2026.
- Business Quant data shows TBPH's Current Assets at $417.6 million in Q1 2026, $418.5 million in Q4 2025, and $354.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 416.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 416.66 Mn |
| Mar 31, 2026 | 417.63 Mn |
| Dec 31, 2025 | 418.46 Mn |
| Sep 30, 2025 | 354.70 Mn |
| Jun 30, 2025 | 366.29 Mn |
| Mar 31, 2025 | 150.26 Mn |
| Dec 31, 2024 | 161.07 Mn |
| Sep 30, 2024 | 116.48 Mn |
| Jun 30, 2024 | 119.31 Mn |
| Mar 31, 2024 | 124.29 Mn |
| Dec 31, 2023 | 133.54 Mn |
| Sep 30, 2023 | 161.69 Mn |
| Jun 30, 2023 | 192.00 Mn |
| Mar 31, 2023 | 261.34 Mn |
| Dec 31, 2022 | 353.46 Mn |
| Sep 30, 2022 | 511.72 Mn |
| Jun 30, 2022 | 154.73 Mn |
| Mar 31, 2022 | 204.64 Mn |
| Dec 31, 2021 | 249.87 Mn |
| Sep 30, 2021 | 297.17 Mn |